146 related articles for article (PubMed ID: 30234387)
21. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
22. [Chivalrous pathology].
Viallard JF; Cony-Makhoul P; Parrens M; Viallard M; Reiffers J; Pellegrin JL; Leng B
Rev Med Interne; 1999; 20 Suppl 2():317s-319s. PubMed ID: 10422186
[No Abstract] [Full Text] [Related]
23. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
24. Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma.
Kato H; Kagami Y; Kodaira T; Oka S; Oki Y; Chihara D; Taji H; Yatabe Y; Nakamura T; Nakamura S; Seto M; Yamamoto K; Morishima Y
Am J Gastroenterol; 2011 Mar; 106(3):549-51. PubMed ID: 21378774
[No Abstract] [Full Text] [Related]
25. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
26. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
27. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Flinn IW; Thompson DS; Boccia RV; Miletello G; Lipman A; Flora D; Cuevas D; Papish SW; Berdeja JG
Br J Haematol; 2018 Feb; 180(3):365-373. PubMed ID: 29193021
[TBL] [Abstract][Full Text] [Related]
28. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
29. Gastric malt lymphoma mickmicking a submucosal tumor with complete response after chemotherapy.
Meriam S; Norsaf B; Dorra T; Asma O; Ehsen BB
Presse Med; 2018; 47(7-8 Pt 1):709-710. PubMed ID: 30032924
[No Abstract] [Full Text] [Related]
30. MALT lymphoma of initial gastric site relapsing as simultaneous bilateral palpebral and salivary glands localizations.
Bauduer F; Robin H; Labadie JC; Darrasse D
Presse Med; 2014 Dec; 43(12 Pt 1):1387-8. PubMed ID: 25307442
[No Abstract] [Full Text] [Related]
31. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
32. [MALT-lymphoma].
Flieger D; Fischbach W
Praxis (Bern 1994); 2006 Aug; 95(31-32):1163-8. PubMed ID: 16909683
[TBL] [Abstract][Full Text] [Related]
33. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
[TBL] [Abstract][Full Text] [Related]
34. Successful Treatment of a Patient With Gastric Mucosa-Associated Lymphoma.
Kothadia JP; Kone V; Raza A
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):e79. PubMed ID: 28899669
[No Abstract] [Full Text] [Related]
35. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy is an effective first line treatment for early stage gastric mucosa-associated lymphoid tissue lymphoma.
Yoon SS; Hochberg EP
Cancer Treat Rev; 2006 Apr; 32(2):139-43. PubMed ID: 16524666
[No Abstract] [Full Text] [Related]
38. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
39. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
40. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T
Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
